ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Boryung Pharmaceutical and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Boryung PharmaceuticalMerck
studies on the registry1432,453
open to participants now23145
phase 3 studies under way1112
reach primary completion within a year760
programswith a study of their own in two years1884

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseBoryung PharmaceuticalMerck
Phase 1

Boryung Pharmaceutical: 8 of its 18 programs at phase 1

  1. BR1015phase 1
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR2021phase 1
  5. olaparibphase 1

and 3 more — sign in to see them all

44%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Boryung Pharmaceutical: 9 of its 18 programs at phase 2

  1. bosmolisibphase 2
  2. BR1400-1phase 2
  3. BR1400-2phase 2
  4. BR1400-3phase 2
  5. BR1400phase 2

and 4 more — sign in to see them all

50%
23%
Phase 3

Boryung Pharmaceutical: 1 of its 18 programs at phase 3

  1. Pioglitazonephase 3
6%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies00%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Boryung Pharmaceutical9 readouts · 0 phase 3···

Boryung Pharmaceutical, Feb ’27: 5 programs whose next study reaches primary completion

  1. BR1400phase 2 · Feb 1 · NCT07373613
  2. BR1400-1phase 2 · Feb 1 · NCT07373613
  3. BR1400-2phase 2 · Feb 1 · NCT07373613
  4. BR1400-3phase 2 · Feb 1 · NCT07373613
  5. BR1400-4phase 2 · Feb 1 · NCT07373613
··

Boryung Pharmaceutical, May ’27: 3 programs whose next study reaches primary completion

  1. BR5402Aphase 2 · May 0 · NCT06821945
  2. BR5402Bphase 2 · May 0 · NCT06821945
  3. BR5402D-1phase 2 · May 0 · NCT06821945
···

Boryung Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion

  1. bosmolisibphase 2 · Sep 0 · NCT07180771
·
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Boryung Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 13 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionBoryung PharmaceuticalMerck
Neoplasmsboth · compare here

Boryung Pharmaceutical in Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Boryung Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Diabetes Mellitus, Type 2both · compare here

Boryung Pharmaceutical in Diabetes Mellitus, Type 2: 5 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1
  4. BR3006phase 1
  5. BR3409phase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Ovarian Neoplasmsboth · compare here

Boryung Pharmaceutical in Ovarian Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Ovarian Neoplasms in search

Alzheimer Diseaseboth · compare here

Boryung Pharmaceutical in Alzheimer Disease: 1 program

  1. Pioglitazonephase 3

Their studies: Boryung Pharmaceutical’s studies of Alzheimer Disease in search

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Breast Neoplasmsboth · compare here

Boryung Pharmaceutical in Breast Neoplasms: 1 program

  1. olaparibphase 1

Their studies: Boryung Pharmaceutical’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Diabetes Mellitusboth · compare here

Boryung Pharmaceutical in Diabetes Mellitus: 3 programs

  1. Pioglitazonephase 3
  2. dapagliflozinphase 1
  3. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Boryung Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. bosmolisibphase 2

Their studies: Boryung Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Obesityboth · compare here

Boryung Pharmaceutical in Obesity: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Fastingboth · compare here

Boryung Pharmaceutical in Fasting: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Fasting in search

Merck in Fasting: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Fasting in search

Hypertensionboth · compare here

Boryung Pharmaceutical in Hypertension: 1 program

  1. BR1015phase 1

Their studies: Boryung Pharmaceutical’s studies of Hypertension in search

Merck in Hypertension: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Hypertension in search

Polycystic Ovary Syndromeboth · compare here

Boryung Pharmaceutical in Polycystic Ovary Syndrome: 1 program

  1. Metforminphase 1

Their studies: Boryung Pharmaceutical’s studies of Polycystic Ovary Syndrome in search

Merck in Polycystic Ovary Syndrome: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Polycystic Ovary Syndrome in search

Show all 13

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetBoryung PharmaceuticalMerck
COXFA4MetforminruleMetforminrule
COXFA4L2MetforminruleMetforminrule
GPD2MetforminruleMetforminrule
MT-ND1MetforminruleMetforminrule
MT-ND2MetforminruleMetforminrule
MT-ND3MetforminruleMetforminrule
MT-ND4MetforminruleMetforminrule
MT-ND4LMetforminruleMetforminrule
MT-ND5MetforminruleMetforminrule
MT-ND6MetforminruleMetforminrule
NDUFA1MetforminruleMetforminrule
NDUFA10MetforminruleMetforminrule
NDUFA11MetforminruleMetforminrule
NDUFA12MetforminruleMetforminrule
NDUFA13MetforminruleMetforminrule
NDUFA2MetforminruleMetforminrule
NDUFA3MetforminruleMetforminrule
NDUFA5MetforminruleMetforminrule
NDUFA6MetforminruleMetforminrule
NDUFA7MetforminruleMetforminrule
NDUFA8MetforminruleMetforminrule
NDUFA9MetforminruleMetforminrule
NDUFAB1MetforminruleMetforminrule
NDUFAF1MetforminruleMetforminrule
NDUFAF2MetforminruleMetforminrule
NDUFAF3MetforminruleMetforminrule
NDUFAF4MetforminruleMetforminrule
NDUFB1MetforminruleMetforminrule
NDUFB10MetforminruleMetforminrule
NDUFB11MetforminruleMetforminrule
NDUFB2MetforminruleMetforminrule
NDUFB3MetforminruleMetforminrule
NDUFB4MetforminruleMetforminrule
NDUFB5MetforminruleMetforminrule
NDUFB6MetforminruleMetforminrule
NDUFB7MetforminruleMetforminrule
NDUFB8MetforminruleMetforminrule
NDUFB9MetforminruleMetforminrule
NDUFC1MetforminruleMetforminrule
NDUFC2MetforminruleMetforminrule
NDUFS1MetforminruleMetforminrule
NDUFS2MetforminruleMetforminrule
NDUFS3MetforminruleMetforminrule
NDUFS4MetforminruleMetforminrule
NDUFS5MetforminruleMetforminrule
NDUFS6MetforminruleMetforminrule
NDUFS7MetforminruleMetforminrule
NDUFS8MetforminruleMetforminrule
NDUFV1MetforminruleMetforminrule
NDUFV2MetforminruleMetforminrule
NDUFV3MetforminruleMetforminrule
A target, or a pathogen for a vaccine, known for: Boryung Pharmaceutical 5 of 18 · Merck 40 of 84 programs (17 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.